]>
IRCT20190928044909N1 IRCT 2020-07-21 Shahid Beheshti University of Medical Sciences Effect of olanzapine in delirium of poisoning patient Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium patient admitted in ICU 2018-11-22 anticipated 36 Complete https://irct.ir/trial/42569 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: We randomly generated 6 blocks for the study intervention and then generated random numbers from the computer and then arranged the blocks on them and then randomly assigned each group to each individual randomization unit. . Hiding is also done by using randomly formatted encrypted boxes, Blinding description: The medication is given to the nurse in anonymous envelopes by the nurse and noted in the questionnaire form.The patient does not know the type of medication. 3 delirium patient admitted in ICU. Intervention 1: Intervention group: olanzapine pill 5 mg, made by Marham Daroo Company and is prescribed orally every 8 hours to three days. Intervention 2: Control group: Halopiridolis pill 5 mg, made by Iran Daroo Company and is prescribed orally every 8 hours to three days. Yes - There is a plan to make this available What will be shared: The protocols will be posted on the Poisoning Center website When: Access started in 1399 To whom: Researchers Working in Academic and Scientific Institutions Conditions: Used only in scientific medical research Where to obtain: With permission from the Director of Loghman Hospital Poisoning Research Center How to obtain: Written request from Loghman Poisoning Center Comments:
public Javad Mesbahi
Loghman Hospital, Makhsoos St, South Karegar Ave.
Tehran Iran (Islamic Republic of) 000002155419005 +98 21 5541 9005 j.mesbahi1969@gmail.com Shahid Beheshti University of Medical Sciences scientific Javad Mesbahi
Loghman Hospital, Makhsoos St, South Karegar Ave
Tehran Iran (Islamic Republic of) 1333631151 +98 21 5541 9005 J.Mesbahi1969@gmail.com Shahid Beheshti University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria included patients over 18 years of age who had acute intoxication without dementia 18 years 80 years Both Patients who take antipsychotic drugs for any reason Patients are using alcohol or benzodiazepine Patients who were allergic to haloperidol or olanzapine, Patients who have severe agitation Treatment - Drugs Treatment - Drugs Intervention group: olanzapine pill 5 mg, made by Marham Daroo Company and is prescribed orally every 8 hours to three days Control group: Halopiridolis pill 5 mg, made by Iran Daroo Company and is prescribed orally every 8 hours to three days. Changes in the symptoms of delirium: All symptoms related to decreased attention and memory impairment are eliminated. Response to treatment is based on changes in MDAS scores.impairment are resolved. The response to treatment is based on improvement in the MDAS score. Timepoint: Treatment results are evaluated by the researcher on days 3 and 5. Method of measurement: Delirio intensity is measured on the MDAS score, which includes 10 items and 4 points.This intensity will be rated in MDAS <= 15 as "mild", in 16 <= MDAS <= 22 as "moderate" and in 23 <= MDAS <= 30, it will be rated "severe". The remission index for this disease based on this score is MDAS values less than 10. Poisoning Research Center Approved 2019-11-25 National Committee on Ethics in Biomedical Research Loghman Hospital,Makhsos Ave Tehran Tehran Iran (Islamic Republic of)